The MET Family of Receptor Tyrosine Kinases Promotes a Shift to Pro-Tumor Metabolism

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2024 Jul 27

PMID 39062731

Authors

James C Davis

Susan E Waltz

Affiliations

Soon will be listed here.

Abstract

The development and growth of cancer is fundamentally dependent on pro-tumor changes in metabolism. Cancer cells generally shift away from oxidative phosphorylation as the primary source of energy and rely more heavily on glycolysis. Receptor tyrosine kinases (RTKs) are a type of receptor that is implicated in this shift to pro-tumor metabolism. RTKs are important drivers of cancer growth and metastasis. One such family of RTKs is the MET family, which consists of MET and RON (MST1R). The overexpression of either MET or RON has been associated with worse cancer patient prognosis in a variety of tumor types. Both MET and RON signaling promote increased glycolysis by upregulating the expression of key glycolytic enzymes via increased MYC transcription factor activity. Additionally, both MET and RON signaling promote increased cholesterol biosynthesis downstream of glycolysis by upregulating the expression of SREBP2-induced cholesterol biosynthesis enzymes via CTTNB1. These changes in metabolism, driven by RTK activity, provide potential targets in limiting tumor growth and metastasis via pharmacological inhibition or modifications in diet. This review summarizes pro-tumor changes in metabolism driven by the MET family of RTKs. In doing so, we will offer our unique perspective on metabolic pathways that drive worse patient prognosis and provide suggestions for future study.

Citing Articles

RON receptor tyrosine kinase regulates glycolysis through MAPK/CREB signaling to affect ferroptosis and chemotherapy sensitivity of thyroid cancer cells.

Jin X, Zhu H, Chen X, Yang Y, Song D Mol Med Rep. 2024; 30(6).

PMID: 39422033 PMC: 11529188. DOI: 10.3892/mmr.2024.13359.

References

Cui J, Zhao S, Chen H, Fu Y, Han K, Yin S . Methylseleninic acid overcomes gefitinib resistance through asparagine-MET-TOPK signaling axis in non-small cell lung cancer cells. Biochem Pharmacol. 2023; 215:115690. DOI: 10.1016/j.bcp.2023.115690. View

Huang X, Gan G, Wang X, Xu T, Xie W . The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019; 15(7):1258-1279. PMC: 6613896. DOI: 10.1080/15548627.2019.1580105. View

Lu Y, Yao H, Wang M . Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160. J Exp Clin Cancer Res. 2008; 27:55. PMC: 2584002. DOI: 10.1186/1756-9966-27-55. View

Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio P . Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res. 2011; 71(5):1945-55. DOI: 10.1158/0008-5472.CAN-10-2100. View

LeBleu V, OConnell J, Gonzalez Herrera K, Wikman H, Pantel K, Haigis M . PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014; 16(10):992-1003, 1-15. PMC: 4369153. DOI: 10.1038/ncb3039. View

Song K, Ellis E, Strom S, Chiang J . Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes. Hepatology. 2007; 46(6):1993-2002. DOI: 10.1002/hep.21878. View

Luo J, Yang H, Song B . Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2019; 21(4):225-245. DOI: 10.1038/s41580-019-0190-7. View

Zhang K, Zhu W, Wang S, Gao C, Pan J, Du Z . Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics. 2021; 11(13):6560-6572. PMC: 8120208. DOI: 10.7150/thno.55609. View

Carr B, Wang Z, Wang M, Cavallini A, DAlessandro R, Refolo M . c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther. 2011; 12(6):531-8. DOI: 10.4161/cbt.12.6.16053. View

10.

Patra K, Hay N . The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39(8):347-54. PMC: 4329227. DOI: 10.1016/j.tibs.2014.06.005. View

11.

Topel H, Bagirsakci E, Yilmaz Y, Gunes A, Bagci G, Comez D . High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. Sci Rep. 2021; 11(1):11376. PMC: 8166976. DOI: 10.1038/s41598-021-89765-5. View

12.

Xiao M, Xu J, Wang W, Zhang B, Liu J, Li J . Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp Mol Med. 2023; 55(9):1982-1995. PMC: 10545798. DOI: 10.1038/s12276-023-01079-w. View

13.

Zinser G, Leonis M, Toney K, Pathrose P, Thobe M, Kader S . Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006; 66(24):11967-74. DOI: 10.1158/0008-5472.CAN-06-2473. View

14.

Moxley K, Wang L, Welm A, Bieniasz M . Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes Cancer. 2016; 7(5-6):169-81. PMC: 4979590. DOI: 10.18632/genesandcancer.109. View

15.

He M, Jiang W, Li X, Liu H, Ren H, Lin Y . 25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/TNFRSF17 axis. BMC Cancer. 2024; 24(1):505. PMC: 11034116. DOI: 10.1186/s12885-024-12227-4. View

16.

Johnson A, Zinser G, Waltz S . Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity. Oncotarget. 2015; 6(18):16304-20. PMC: 4599271. DOI: 10.18632/oncotarget.4059. View

17.

Fernie A, Carrari F, Sweetlove L . Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol. 2004; 7(3):254-61. DOI: 10.1016/j.pbi.2004.03.007. View

18.

Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F . SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004; 86(11):839-48. DOI: 10.1016/j.biochi.2004.09.018. View

19.

Guerin C, Tulasne D . Recording and classifying MET receptor mutations in cancers. Elife. 2024; 13. PMC: 11042802. DOI: 10.7554/eLife.92762. View

20.

Hanau S, Helliwell J . 6-Phosphogluconate dehydrogenase and its crystal structures. Acta Crystallogr F Struct Biol Commun. 2022; 78(Pt 3):96-112. PMC: 8900737. DOI: 10.1107/S2053230X22001091. View